Evidence map›Paper›PMID 26717565›Full record

ArticlePloS one2015

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas.

Rajyasree Emmadi, Emanuele Canestrari, Zarema H Arbieva, Wenbo Mu, Yang Dai, Jonna Frasor, Elizabeth Wiley

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. G2/M Checkpoint Modulation: Insights from miRNA Profiles in FAM and Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Rajyasree EmmadiDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Emanuele CanestrariCenter for Pharmaceutical Biotechnology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Zarema H ArbievaCore Genomics Facility, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Wenbo MuDepartment of Bioengineering, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Yang DaiDepartment of Bioengineering, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Jonna FrasorDepartment of Physiology and Biophysics, University of Illinois at Chicago, Chicago, Illinois, United States of America.
Elizabeth WileyDepartment of Pathology, University of Illinois at Chicago, Chicago, Illinois, United States of America.
University of Illinois Chicago · US

Funding

Crosstalk between estrogen receptor and NFkB in target gene regulationR01CA130932 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI FRASOR, JONNA · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA130932NCI NIH HHS R01 CA130932-05
6 · The paper itself

Abstract

Altered expression of miRNAs has been observed in many types of cancer, including breast cancer, and shown to contribute to cancer growth, aggressiveness, and response to therapies. In this pilot study, we investigated the possible correlation of miRNAs with risk of recurrence of estrogen receptor positive, lymph node-negative mammary carcinomas as determined by the Oncotype DX® Breast Cancer assay. To accomplish this, we extracted RNA from a collection of breast carcinomas that had previously been analyzed by Oncotype DX®. Multiple Let-7 family members were negatively correlated with the recurrence score (RS), which is consistent with their tumor suppressor properties. Additional miRNAs were found to positively correlate with RS, including miR-377-5p, miR-633b, miR-548t and miR-3648. Pathway analysis of putative and validated targets suggests that these miRNAs may have a diverse range of functions that may contribute to tumor recurrence. Taken together, these findings provide evidence that a miRNA expression signature can be developed to aid existing methods to determine the risk of recurrence for women with estrogen receptor positive breast cancers treated with endocrine therapy.

Indexed as

AdultAgedBiomarkers, TumorBreast NeoplasmsFemaleGene Expression ProfilingHumansKi-67 AntigenMicroRNAsMiddle AgedNeoplasm Recurrence, LocalPrognosisReceptors, EstrogenRetrospective StudiesRisk AssessmentBiomarkers, TumorKi-67 AntigenMicroRNAsReceptors, Estrogen

Identifiers

PMID26717565
PMCPMC4696739
OpenAlexW2201044037

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.